The manufacturer didn't apply for EUA because the European trial was a mess, and there was basically no chance of FDA approval based on the data they had.
The FDA is already reluctant to use trials from jurisdictions that may be very different demographically. When the trials are marginal, confused, and confounded, the chance of a FDA approval become negligible.
If the AZ US trial pops out good data, you can expect a speedy EUA application.
The us trail has completed with appearently good data. This just came out today so no surprise you didn't know about it yet.
So it seems! So, yes, that's a nice bonus if it gets authorized here.
Probably the same reason why the manufacturer hasn't requested EU approval of the Dutch plant where they manufacture vaccines exported to the UK. That is, to make more money.
There might be perfectly valid reasons for this- I am not sure to what extent the government could or would want to force it to fast-track.